Natera Files Second Quarter 10-Q With SEC as Federal Reserve Decisions Loom
The genetic testing company submitted its quarterly report to regulators as investors await upcoming Fed policy meetings and the firm's next earnings release.
Regulatory Filing Submitted
Natera, Inc. (NASDAQ: NTRA) filed its quarterly 10-Q report with the Securities and Exchange Commission on August 7, 2026, according to SEC EDGAR filings. The submission represents the company's required disclosure for its most recent fiscal quarter.
The genetic testing company, which focuses on reproductive health and oncology diagnostics, closed at $265.38 per share and currently commands a market capitalization of approximately $38 billion.
Recent Insider Transactions
MarginX data shows recent insider selling activity at the company. Michael Burkes Brophy sold 478 shares, while Steven Leonard Chapman disposed of 160 shares. Solomon Moshkevich conducted the largest reported transaction, selling 1,233 shares. Such routine insider sales are commonly scheduled in advance and may reflect personal financial planning rather than views on company prospects.
Upcoming Market Events
Investors in Natera will be monitoring several significant dates in the coming months. The Federal Reserve is scheduled to announce its rate decision alongside economic projections on September 16, 2026, followed by another FOMC decision on October 28, 2026. These monetary policy decisions could influence broader market conditions for growth-oriented healthcare technology companies.
According to MarginX data, Natera is expected to report its third quarter 2026 results on November 6, 2026, which will provide investors with updated financial performance metrics and management commentary on the business trajectory.
Company Position
Natera operates in the molecular diagnostics sector, offering non-invasive prenatal testing, carrier screening, and oncology testing services. The company's market valuation places it among the significant players in the genetic testing industry as healthcare providers increasingly adopt precision medicine approaches.
The 10-Q filing will provide detailed financial statements, management discussion and analysis, and disclosures regarding risk factors affecting the business during the reporting period.
This article was generated by MarginX from public news on 2026-08-07. It is not investment advice.